Dry Powder Inhaler Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033

"The new report published by The Business Research Company, titled ""Dry Powder Inhaler Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the dry powder inhaler market size has grown strongly in recent years. It will grow from $20.18 billion in 2023 to $21.25 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $25.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13430&type=smp

Rising Prevalence Of Respiratory Diseases Fuels Growth In The Dry Powder Inhaler Market
The growing prevalence of respiratory diseases is expected to propel the growth of the dry powder inhaler market going forward. Respiratory diseases refer to respiratory disorders or lung diseases, encompassing a broad category of medical conditions affecting the respiratory system. Dry powder inhalers are essential in treating respiratory conditions such as asthma, COPD, and cystic fibrosis as they deliver medicine directly to the lungs, where it is most effective. It is a promising alternative to traditional drug delivery methods for respiratory diseases. For instance, in June 2023, according to reports published by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021 in Australia. Therefore, the growing prevalence of respiratory diseases will drive the growth of the dry powder inhaler market.

Innovative Products And Market Expansion Strategies In The Dry Powder Inhaler (DPI) Market
Major companies operating in the dry powder inhaler market are developing innovative products with muscarinic antagonist for treating chronic obstructive pulmonary disease (COPD) and expanding their product portfolio. A muscarinic antagonist is a drug that inhibits the muscarinic acetylcholine receptor. It controls and treats various illnesses, such as COPD and organophosphate poisoning. For instance, in June 2021, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched Tiogiva, a long-acting muscarinic antagonist dry powder inhaler (DPI) that is used to treat chronic obstructive pulmonary disease (COPD) in the UK. It is the bioequivalent generic version of Boehringer-Ingelheim's Spiriva Handihaler. It functions by calming the muscles in the airways, which facilitates breathing. It is taken once a day and is indicated for the long-term maintenance treatment of COPD in adults. Moreover, it is easy to use and does not require a spacer.

The dry powder inhaler market covered in this report is segmented -

1) By Product: Single-Dose Inhalers, Multi-Dose Inhalers
2) By Function: Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Other Applications
4) By End User: Hospitals And Clinics, Homecare Settings, Ambulatory Surgical Centers, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13430&type=discount

Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline Plc, 3M Company , Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd, Beximco Pharmaceuticals Ltd, Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals , Presspart Manufacturing Ltd, SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.

Contents of the report:
1. Executive Summary
2. Dry Powder Inhaler Market Report Structure
3. Dry Powder Inhaler Market Trends And Strategies
4. Dry Powder Inhaler Market - Macro Economic Scenario
5. Dry Powder Inhaler Market Size And Growth
…..
27. Dry Powder Inhaler Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/dry-powder-inhaler-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.